HEALTH 

Bayer antibody-drug conjulate (ADC) misses in phase 2 mesothelioma trial

Bayer antibody-drug conjulate (ADC) misses in phase 2 mesothelioma trial

Bayer’s antibody-drug conjulate (ADC) anetumab ravtansine has failed to show improvements in the survival rates of mesothelioma patients. Stock prices of Bayer’s collaborators ImmunoGen and MorphoSys declined as the announcement was made.
Malignant pleural mesothelioma is a rare…

www.theleader.info/2017/07/26/bayer-antibody-drug-conjula…

Posted by theleaderdotinfo on 2017-07-26 19:38:33

Tagged: , anetumab ravtansine , Bayer , business , health , ImmunoGen , mesothelioma , MorphoSys , vinorelbine

Related posts